貝伐單抗

Bevacizumab is a humanized IgG1 monoclonal antibody designed to bind with high affinity to all isoforms of vascular endothelial growth factor A (VEGF-A). This specific interaction inhibits the biological activity of VEGF-A, which plays a critical role in angiogenesis and the promotion of tumor growth. Bevacizumab is utilized extensively in research focused on cancer therapy, particularly in studies exploring the mechanisms of angiogenesis inhibition in tumor progression.